
浏览全部资源
扫码关注微信
广西中医药大学 药学院,南宁 530001
顾嘉琪,在读硕士,从事中药药性理论与临床研究,E-mail:gujiaqi000@126.com
许强,博士,讲师,从事六经辨治内分泌疾病研究,E-mail:tcmhacker@sina.com
收稿日期:2022-12-08,
网络出版日期:2023-03-21,
纸质出版日期:2023-06-20
移动端阅览
顾嘉琪,覃骊兰,苏榕等.肉桂对糖尿病大鼠肠促胰素效应的调节作用[J].中国实验方剂学杂志,2023,29(12):104-111.
GU Jiaqi,QIN Lilan,SU Rong,et al.Cinnamomi Cortex Regulates Incretin Effect in Diabetic Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(12):104-111.
顾嘉琪,覃骊兰,苏榕等.肉桂对糖尿病大鼠肠促胰素效应的调节作用[J].中国实验方剂学杂志,2023,29(12):104-111. DOI: 10.13422/j.cnki.syfjx.20230438.
GU Jiaqi,QIN Lilan,SU Rong,et al.Cinnamomi Cortex Regulates Incretin Effect in Diabetic Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(12):104-111. DOI: 10.13422/j.cnki.syfjx.20230438.
目的
2
探讨通过建立链脲佐菌素(STZ)诱导的糖尿病(DM)大鼠模型,观察肉桂对DM大鼠肠促胰素效应的药效学作用,并基于胰高血糖素样肽-1(GLP-1)、二肽基肽酶-4(DPP-4)蛋白探讨其作用机制。
方法
2
40只SD大鼠随机分为空白组、模型组、西格列汀组(0.1 g·kg
-1
)、肉桂低、高剂量组(0.45、0.9 g·kg
-1
),除空白组外采用高脂饲料喂养联合腹腔注射STZ(40 mg·kg
-1
)建立DM大鼠模型。给药干预时间为8周,观察大鼠状态、体质量、饮水量、摄食量、空腹血糖(FBG)等情况,采用苏木素-伊红(HE)染色观察大鼠胰腺病理变化,采用免疫组化法检测DM大鼠胰腺中胰高血糖素蛋白表达,生化法检测大鼠血清脂代谢指标总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)及高密度脂蛋白(HDL)水平。酶联免疫吸附测定法(ELISA)检测大鼠血清中糖化血红蛋白、胰岛素、胰高血糖素、GLP-1、葡萄糖依赖性促胰岛素多肽(GIP)含量。采用蛋白免疫印迹法(Western blot)检测DM大鼠胰腺中GLP-1、DPP-4的蛋白表达。
结果
2
各组干预8周后,与正常组比较,模型组大鼠体质量、空腹血糖、TC、TG、LDL、糖化血红蛋白、胰高血糖素、胰岛素、胰岛素抵抗指数显著升高(
P
<
0.01),HDL、GLP-1、GIP明显降低(
P
<
0.05,
P
<
0.01);与模型组比较,肉桂各剂量组大鼠体质量、空腹血糖、TC、TG、LDL、糖化血红蛋白、胰高血糖素、胰岛素、胰岛素抵抗指数明显降低(
P
<
0.05,
P
<
0.01),HDL、GLP-1、GIP明显升高(
P
<
0.05,
P
<
0.01)。HE染色结果显示,肉桂各剂量组胰岛细胞形态明显好转,未出现细胞核密集现象。免疫组化结果显示,与模型组比较,肉桂各剂量组胰高血糖素蛋白在胰岛细胞中央明显减少,含量下降。Western blot结果显示,与正常组比较,模型组大鼠DPP-4的蛋白表达水平显著升高(
P
<
0.01),GLP-1的蛋白表达水平显著降低(
P
<
0.01);与模型组比较,肉桂高剂量组DPP-4的蛋白表达水平明显降低(
P
<
0.05),GLP-1的蛋白表达水平表达明显升高(
P
<
0.05)。
结论
2
肉桂可有效降低DM大鼠血糖,改善肠促胰素效应,进而发挥降糖作用,作用机制可能是通过激活调控DPP-4和GLP-1蛋白来实现。
Objective
2
To observe the pharmacodynamic effects of Cinnamomi Cortex on the incretin effect in the rat model of diabetes mellites (DM) induced by streptozotocin (STZ) and explore the underlying mechanism from glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4).
Method
2
Forty SD rats were randomly assigned into blank, model, sitagliptin (0.1 g·kg
-1
), and low- and high-dose Cinnamomi Cortex (0.45 and 0.9 g·kg
-1
, respectively) groups. The DM rat model was established by a high-fat diet combined with intraperitoneal injection of 40 mg·kg
-1
STZ in other groups except the blank group. The intervention lasted for 8 weeks. The status, body weight, water intake, food intake, and fasting blood glucose (FBG) of the rats were observed and determined. Hematoxylin-eosin staining was employed to reveal the pathological changes of the pancreas, and immunohistochemistry to detect the expression of glucagon in the pancreas. Biochemical assay was employed to measure the serum levels of lipid metabolism indexes such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Enzyme-linked immunosorbent assay was employed to determine the levels of glycosylated hemoglobin, insulin, glucagon, GLP-1, and glucose-dependent insulinotropic polypeptide (GIP) in rat serum, and Western blot to determine the protein levels of GLP-1 and DPP-4 in the pancreas.
Result
2
After 8 weeks of intervention, the model group showed higher body weight, FBG, TC, TG, LDL, glycosylated hemoglobin, glucagon, insulin, and insulin resistance index and lower HDL, GLP-1, and GIP than the blank group (
P
<
0.05,
P
<
0.01). The Cinnamomi Cortex groups showed lower body weight, FBG, TC, TG, LDL, glycosylated hemoglobin, glucagon, insulin, and insulin resistance index and higher HDL, GLP-1, and GIP than the model group (
P
<
0.05,
P
<
0.01). The Cinnamomi Cortex groups showed recovered morphology of islet cells and no nucleus aggregation. Compared with the model group, the Cinnamomi Cortex groups showed declined levels of glucagon in the center of islet cells. Compared with the blank group, the model group showed up-regulated protein level of DPP-4 and down-regulated protein level of GLP-1 (
P
<
0.01). Compared with the model group, the high-dose Cinnamomi Cortex groups showed down-regulated protein level of DPP-4 and up-regulated protein level of GLP-1 (
P
<
0.05).
Conclusion
2
Cinnamomi Cortex may reduce blood glucose and improve incretin effect to lower the blood glucose level by regulating DPP-4 and GLP-1 in DM rats.
HU C , JIA W . Diabetes in China:Epidemiology and genetic risk factors and their clinical utility in personalized medication [J]. Diabetes , 2018 , 67 ( 1 ): 3 - 11 .
郭立新 . 2021年糖尿病领域年度重大进展回顾 [J]. 中华糖尿病杂志 , 2022 , 14 ( 1 ): 1 - 8 .
MAYENDRARAJ A , ROSENKILDE M M , GASBJERG L S . GLP-1 and GIP receptor signaling in beta cells-a review of receptor interactions and co-stimulation [J]. Peptides , 2022 , 151 : 170749 .
MEGA C , TEIXEIRA-DE-LEMOS E , FERNANDES R , et al . Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin:A review in type 2 diabetes [J]. J Diabetes Res , 2017 , 2017 : 5164292 .
汪健红 , 陆付耳 , 董慧 . 肉桂治疗糖尿病的研究进展 [J]. 中西医结合研究 , 2011 , 3 ( 1 ): 25 - 27,41 .
任艳玲 , 姜开运 . 中药学 [M]. 北京 : 中国中医药出版社 , 2018 .
马如风 , 王丽丽 , 郭鱼波 , 等 . 肉桂治疗2型糖尿病的理论基础及临床研究 [J]. 中国中医基础医学杂志 , 2016 , 22 ( 3 ): 409 - 411 .
穆国华 . 黄连-肉桂治疗T2DM的临床应用及对基于肠道菌群的BA/TGR5/GLP-1通路影响 [D]. 北京 : 北京中医药大学 , 2021 .
王佰涛 , 杨文玲 , 陈国参 , 等 . 肉桂提取物及其活性成分对2型糖尿病改善作用的研究进展 [J]. 中国现代应用药学 , 2021 , 38 ( 10 ): 1269 - 1274 .
卫克昭 . 肉桂及其主要药效成分对糖尿病性心脏病的保护作用和机制研究 [D]. 上海 : 上海中医药大学 , 2019 .
黄湘宁 , 姚心怡 , 谭艳 , 等 . 基于数据挖掘的2型糖尿病动物模型应用分析 [J]. 中国实验方剂学杂志 , 2023 , 29 ( 2 ): 159 - 165 .
杨玥 , 吴晓康 . 中医药干预肠道菌群防治糖尿病的研究进展 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 7 ): 219 - 227 .
冯晓桃 , 程永芳 . 扶阳药肉桂防治糖尿病的科学内涵研究进展 [J]. 世界科学技术—中医药现代化 , 2020 , 22 ( 5 ): 1472 - 1477 .
潘华信 . 附桂抗瘀血论 [J]. 上海中医药大学学报 , 2006 , 20 ( 4 ): 34 - 37 .
SHANG C , LIN H , FANG X , et al . Beneficial effects of cinnamon and its extracts in the management of cardiovascular diseases and diabetes [J]. Food Funct , 2021 , 12 ( 24 ): 12194 - 12220 .
赵丹 , 王明慧 , 张程斐 , 等 . 肉桂酸对db/db小鼠肝脏PI3K/Akt/FoxO1信号通路的影响 [J]. 世界科学技术—中医药现代化 , 2021 , 23 ( 10 ): 3613 - 3620 .
FROST F , JONES G H , DYCE P , et al . Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes [J]. Diabet Med , 2019 , 36 ( 11 ): 1367 - 1374 .
杨叶萍 , 张朝云 . 肠促胰岛素对糖尿病肾病的保护作用及机制 [J]. 中华糖尿病杂志 , 2015 , 7 ( 5 ): 331 - 333 .
陈俊 , 钱紫星 , 朱梦杨 , 等 . 基于GPR119/cAMP/GLP-1通路探讨葛根芩连汤的降糖机制 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 3 ): 25 - 30 .
TAN Q , AKINDEHIN S E , ORSSO C E , et al . Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes [J]. Front Endocrinol (Lausanne) , 2022 , 13 : 838410 .
梁引红 , 师静梅 . 2型糖尿病患者心血管风险和血清胰高血糖素样肽-1水平关系研究 [J]. 中国药物与临床 , 2021 , 21 ( 16 ): 2779 - 2781 .
龙江川 . 利拉鲁肽在超重2型糖尿病患者中的临床治疗结局及其与GLP-1R、DPP-4基因多态性的相关性研究 [D]. 重庆 : 重庆医科大学 , 2020 .
许趁意 , 岳仁宋 , 吕雪莲 , 等 . 基于胆汁酸代谢轮廓研究半夏泻心汤通过FXR/GLP-1途径调控2型糖尿病血糖稳态的机制 [J]. 中华中医药杂志 , 2022 , 37 ( 8 ): 4394 - 4399 .
高芸艺 , 李兰 , 冉兴无 . 二肽基肽酶Ⅳ抑制剂在2型糖尿病治疗中的地位 [J]. 中华糖尿病杂志 , 2016 , 8 ( 11 ): 653 - 657 .
SUN Z G , LI Z N , ZHU H L . The research progress of DPP-4 inhibitors [J]. Mini Rev Med Chem , 2020 , 20 ( 17 ): 1709 - 1718 .
0
浏览量
34
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621